Recomandare: Resveratrol
Sinergie din Farmacia Nasturala este o formula avansata AntiCancer cu fito farmaceutice
ca adjuvant in terapia cancerului:
trans Resveratrol extr. stand. 20%,
50 mg din (Poligonum cuspidatum), Extract din Samburi de Struguri
extr.stand. OPC 95% din: Saminta de Struguri Rosii (Vitis Vinifera),
100 mg, Quercitina extr. stand. 95% 200 mg, Acid Elagic extr. stand.
40% 200 mg, Ceai Verde Supreme extr. stand. EGCG 50%, 200 mg, L-Lizina
250 mg, Vitamina C 250 mg.
Produse naturale din medicina traditionala
Hipertermia efecte terapeutice
- Hipertermia subclinica intre 37°C - 38,5°C cu sprijin terapeutic de vasodilatatie,
cresterea circulatiei sanguine,
- Hipertermia moderata intre 38,5°C - 40°C ca stimulator imunitar,
- Hipertermia intermediara intre 40°C - 41,5°C ca sprijin la tratamentele
citostatice,
- Hipertermia extrema efectuata de medici specialisti intre 41,5°C - 43°C
cu efect de distrugerea celulelor canceroase
2. Relatia timpului de actiune
a caldurii si temperatura la tranzitul de 42°C la 43°C este relevanta la
hipertermia clinica
Hipertermia mecanismele actiunii energiei si a gradientului temperaturii asupra membranei
celulare canceroase si inducerea apoptozei la celulele tumorale
3. Hipertermia un tratament anticancer induce moartea celulara in comparatie
cu alti agenti citotoxici
- EGCG citostatic natural
5. Hipertermia o terapie
anticancer ca adjuvant la radioterapie pentru metastaza
de melanom malign, studiu randomizat trial
6. Radioterapia intensiva inainte de operatie impreuna cu hipertermia locala
la
tratamentul carcinomului gastric
Hipertermia la distrugerea de celule tumorale
Hipertermia world wide web
Bibliografie-Referinte:
1. Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD,
Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson
DA,
Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized
trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Department
of Radiation Oncology, University of California, San Francisco 94143-0226, USA.
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95.
2. Field SB, Morris CC. The relationship between heating time and temperature:
its relevance to clinical hyperthermia. Radiother Oncol. 1983 Nov;1(2):179-86.
3. Vidair CA, Dewey WC. Division-associated and division-independent hyperthermic
cell death: comparison with other cytotoxic agents. Department of Radiation Oncology,
University of California, San Francisco 94143. Int J Hyperthermia. 1991
Jan-Feb;7(1):51-60.
4. Kitamura K, Kuwano
H, Watanabe M, Nozoe T, Yasuda M, Sumiyoshi K, Saku M, Sugimachi
K. Prospective randomized study of hyperthermia combined with chemoradiotherapy
for esophageal carcinoma. Department of Surgery II, Faculty of Medicine, Kyushu
University, Fukuoka, Japan. J Surg Oncol. 1995 Sep;60(1):55-8.
5. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella
O, Bentzen SM. Randomised trial of hyperthermia as adjuvant to radiotherapy
for
recurrent or metastatic malignant melanoma. European Society for Hyperthermic
Oncology. Danish Cancer Society Department of Experimental Clinical Oncology,
Aarhus. Lancet. 1995 Mar 4;345(8949):540-3.
6. Shchepotin IB, Evans SR, Chorny V, Osinsky S, Buras RR, Maligonov P, Shabahang
M, Nauta RJ. Intensive preoperative radiotherapy with local hyperthermia for
the treatment
of gastric carcinoma. Lombardi Cancer Center, Georgetown University, Washington,
DC. Surg Oncol. 1994 Feb;3(1):37-44.
Parerea din pasajele acestui site nu a fost independent cercetate sau confirmate
